Last week saw the official end of the EU-funded VACCELERATE project; through collaboration, innovation, and strategic infrastructure development, the project has established a lasting impact on pandemic preparedness and public health.
VACCELERATE created a network for pandemic preparedness in Europe, planning and coordinating phase 2 & 3 vaccine trials in all EU-member states and EU-associated countries under one strategic-scientific umbrella. It served as a single-entry point for all stakeholders involved in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others).
Key Achievements:
Establishment of a Pan-European Clinical Trial Network
A robust and interconnected network of clinical trial sites was developed across Europe and associated countries, improving coordination and fostering collaboration among researchers, institutions, and stakeholders.
Acceleration of (Vaccine) Trials
By facilitating rapid access to trial sites, expert teams, and harmonized protocols, VACCELERATE played a crucial role in expediting (vaccine) trials. This ensured the timely generation of reliable data for critical decision-making during the COVID-19 pandemic.
Citizen Engagement in (Vaccine) Research
Innovative strategies were implemented to involve the public in (vaccine) research. The establishment of the Volunteer Registry enabled individuals to participate in clinical trials, significantly boosting recruitment and raising awareness of vaccine development.
Data Harmonization and Standardization
Through the creation of standardized protocols and data-sharing mechanisms, VACCELERATE improved the quality and comparability of clinical trial data. By embracing the FAIR principles, the project laid the foundation for future multinational studies.
Training and Capacity Building
Comprehensive training programs for clinical researchers and their teams strengthened expertise in vaccine trials across Europe, enhancing the readiness of clinical sites for future pandemics.
Contribution to Public Health
VACCELERATE’s research included studies on vaccines in under-researched populations, such as the very old and very young, as well as assessments of optimal booster vaccination timing for the general population. These efforts will continue to support global health initiatives in the future.
VACCELERATE has demonstrated the power of collaboration and innovation in addressing global health challenges. By fostering shared resources and expertise, the project has set new standards for vaccine research and pandemic preparedness in Europe. The infrastructure established will continue to support future research and public health initiatives, ensuring long-term benefits beyond the project’s duration. Find out more about this project here: https://vaccelerate.eu/
The project has received funding from the European Union’s HORIZON 2020 research and innovation programme (grant agreement number 101037867). As a network for vaccination research, VACCELERATE has made a significant contribution to coping with the COVID-19 pandemic and emergency preparedness for future pandemics.
Комментарии